An experimental study to evaluate the role of aspirin and metformin in prevention of depression in rats

Alisha Abbas, Narendra Kumar*, Sarvesh Singh, Rahul Kumar, Akhlaque Ahmad, Rajendra Nath, Rakesh Kumar Dixit

INTRODUCTION

Major depressive disorder (MDD) is an extremely prevalent neuropsychiatric disease that affects around twenty five to thirty percent of the patients visiting outpatient departments.\(^1\) Besides the disturbance in monoamine neurotransmitter system, the alteration in hypothalamic-pituitary-adrenal axis (HPA) is also an important contributing factor to the pathology of depression.\(^2\) Increased activity of HPA axis leads to an increase in cortisol level which along with dysfunction of the central serotonergic system has a consequential effect on pathology of depression.\(^3\) Several meta-analyses have gathered the colossal evidence, where pro-inflammatory markers like C reactive protein (CRP), interleukin (IL)-6, tumor necrosis factor (TNF)-\(\alpha\) have been found at increased levels among patients with depression which indicates that the immune system is closely associated with depression.\(^4,5\)

Inflammatory markers like IL-1\(\beta\) regulates the expression of the serotonin transporter gene and IL-6 may also contribute to the inhibition of proliferation.\(^6,7\) This may be consistent with the hypothesis that hippocampal neurogenesis is necessary for the treatment of depression. It was also postulated that IL-6 can be utilised as a new...
target for the therapy of depression.\textsuperscript{8} TNF-\(\alpha\) could activate HPA axis and directly activate indoleamine-2,3-dioxygenase (IDO), which is expressed in macrophages and dendritic cells in the brain and then through kynurenine pathway catabolize tryptophan which is the substrate for serotonin synthesis.\textsuperscript{9,10}

Considering the role of inflammatory pathology in depression, this study was designed to look for the preventive role of anti-inflammatory drugs in stress induced model of depression in Wistar rats. The drugs used in this study were aspirin and metformin.

Aspirin cause irreversible inhibition of cyclooxygenase enzyme by covalently modifying COX-1 and COX-2 activity.\textsuperscript{11} Aspirin had been studied and in use for a wide variety of disorders like prevention of thrombus formation in patients of myocardial infarction and stroke, it is also used in the prevention of wide variety of cancers like colon cancer.\textsuperscript{12} According to the study, COX-1 and COX-2 are involved in neuroinflammation for leucocyte recruitment and reduction in COX-1 activity is beneficial in inflammation reduction. According to an experiment conducted by Choi et al, intracerebroventricular LPS induced neuroinflammation was attenuated in COX-1 mice as compared to COX-2 mice. They also conducted another study to show the response of COX-1 gene deletion on neuroinflammation.\textsuperscript{13}

Metformin is a drug classified under the biguanide family of anti-diabetic medications and is primarily used to treat hyperglycaemia and insulin resistance in type 2 diabetic patients and can be safely given for long term.\textsuperscript{14}

Besides its use in diabetes Metformin has lots of other pleiotropic effects like it was seen beneficial in cardiovascular diseases and various types of cancers with very few adverse effects.\textsuperscript{15} It was also been demonstrated that metformin could inhibit nuclear factor-\(\kappa B\) (NF-\(\kappa B\)) signalling. NF-\(\kappa B\) is involved in the pathophysiology of various diseases like diabetes mellitus (DM) and cardiovascular disease (CVD).\textsuperscript{16} By making NF-\(\kappa B\) as one of its targets it could be helpful in all those inflammatory pathologies in which is involved as a contributing factor.\textsuperscript{17} So we hypothesised that because of its anti-inflammatory potential of aspirin and metformin they might have some effect in the prevention of Depression.

**METHODS**

After being approved from institutional animal ethics committee (97/IAEC/2018 dated- 20/8/2018) study was carried out in 54 healthy adult albino wistar rats of either sex, who were not different in their age and body weight (150-200gm) and were kept under standard laboratory conditions of temperature and humanity (25±2\(^\circ\)C, 70%). They were provided pellet food and water ad libitum with 12 hours light/dark cycle except on days of stress. Rats were bought to the laboratory one week before starting the experiment. After one week of acclimatisation rats were randomly divided into 9 groups of 6 rats in each group as group I was normal control, group II was stress control, group III was treated with aspirin (30 mg/kg), group IV was treated with aspirin (60 mg/kg), group V was metformin (50 mg/kg), group VI was metformin (100 mg/kg), group VII was treated aspirin (30 mg/kg) with metformin (50 mg/kg) combination, group VIII was treated with combination of aspirin (60 mg/kg) and metformin (100 mg/kg), group IX was imipramine (15 mg/kg) treated group. All the drugs were given per orally by dissolving in distilled water. During the entire course of the study, the standard protocols were followed. Powdered forms of aspirin and metformin were purchased from HIMEDIA, sucrose powder was purchased from Fischer chemicals and imipramine powder was purchased from TCI chemicals.

Model of depression was created by the induction of chronic unpredictable mild stress (CUMS). The CUMS procedure is the variation of methods as described in the previous literature.\textsuperscript{18}

| Table 1: Schedule of CUMS for 28 days. |
|---------------------------------------|
| **Monday** | **Tuesday** | **Wednesday** | **Thursday** | **Friday** | **Saturday** | **Sunday** |
| W1 | **Tail pinch 5 min** | Confined space 90 min | **Water deprivation 24 hours** | **Tilted cage 90 min** | Confined space 90 min | **Tail pinch 5 min** | **Food deprivation 24 hours** |
| W2 | **Confined space 90 min** | Tilted cage 90 min | **Tail pinch 5 min** | **Water deprivation 24 hours** | **Tilted cage 90 min** | Confined space 90 min | **Food deprivation 24 hours** |
| W3 | **Tail pinch 5 min** | Confined space 90 min | **Food deprivation 24 hours** | **Tilted cage 90 min** | **Water deprivation 24 hours** | Tilted cage 90 min | **Tail pinch 5 min** |
| W4 | **Water deprivation 24 hours** | Tilted cage 90 min | Confined space 90 min | **Tail pinch 5 min** | Confined space 90 min | Tilted cage 90 min | **Food deprivation 24 hours** |

CUMS- chronic unpredictable mild stress; W1- week 1, W2- week 2, W3- week 3, W4- week 4.
The stressors for CUMS were applied each day for consecutive 28 days in all the groups except the normal control. The stressors include tail pinch for 5 min, confined space for 90 min, Water deprivation for 24 hours, food deprivation for 24 hours, tilted cage at 45 degrees for 90 min. The stressors were applied with the pre decided schedule as given in Table 1. The stress schedule was changed every week to avoid habituation of the rats to the stress.\textsuperscript{10} Respective drugs were given along with CUMS for 4 weeks every morning at a fixed time to the treatment groups and distilled water at the same time to control groups.

**Behavioural tests**

**Forced swim test:** Forced swim test (FST) was done in the transparent cylinder of height 40 cm and diameter of 20 cm. It was filled with water up to the depth of 30 cm and then the rats were placed in the cylinder. Initially the rats showed excessive activity and tried to escape. After some time they reduce their activity and eventually became “immobile”. Rat was considered to be immobile when they did only that much movements that were essential to keep its head above water. At day 0 only habituation session of the rats were done in the FST apparatus to make them familiar with the process. The test session was started after 24 hours on day 1.

On day 1, FST test session was performed for 5 min and the duration of immobility was recorded in all the groups. FST test session was performed again on day 2, after 1 hour of giving the respective treatment to each group. Then final assessment was done at day 28. The water was changed after each animal testing. The changes in immobility duration were recorded on day 1, day 2 and day 28.

**Sucrose preference test:** Anhedonia in rats can also be measured by another behavioural test that is sucrose preference test. At day 1 after a 12-hour period of food and water deprivation, rats were given free access to either of two bottles containing 1% sucrose solution or water provided in their cages. The positions of the two bottles were switched after 30 min to avoid position preference. After 1 hour, the volumes of consumed sucrose solution and water were recorded. The changes in sucrose preference ratio were recorded on day 1 and day 28. The sucrose preference ratio (SPR) were calculated according to the following equation: \textsuperscript{20} 

$$SPR = \frac{\text{Sucrose intake (ml)}}{\text{Sucrose intake (ml)} + \text{Water intake (ml)}}$$

Data were summarised as mean±SD. Intergroup comparisons of immobility duration in FST and SPR were done using analysis of variance (ANOVA) followed by post hoc Tukey’s Honestly significant difference (HSD) test. A p value of <0.05 was considered statistically significant.

**RESULTS**

**Assessment of anti-depressant activity using forced swim test**

Inter group comparison was done using ANOVA test at day 1, day 2 and day 28 as shown in Table 2. On day 1, mean duration of immobility ranged from 62.17±5.00 sec to 66.67±3.72 sec. Statistically, the intergroup differences were not significant (p=0.456). On day 2, mean duration of immobility ranged from 64.33±1.37 sec to 73.50±10.31 sec. Statistically, there was no significant intergroup difference in mean immobility times (p=0.256). While on day 28, mean duration of immobility ranged from 61.83±2.32 sec to 136.17±4.96 sec. Statistically, the intergroup differences were significant (p<0.001).

**Assessment of anti-depressant activity using sucrose preference ratio**

Inter group comparison of sucrose preference ratio before inducing CUMS at day1 and after inducing CUMS at day 28 was done using ANOVA as shown in table 3. Before induction of CUMS at Day 1 mean SPR values ranged from 0.900±0.026 to 0.920±0.033, however the intergroup differences as assessed by ANOVA were not found to be significant (p=0.989). After induction of CUMS mean SPR values ranged from 0.523±0.077 to 0.908±0.022. Statistically, the intergroup differences were significant (p<0.001).

**Table 2: Intergroup comparisons of duration of immobility in FST using ANOVA at day 1, day 2 and day 28.**

| Groups | Day 1 | Day 2 | Day 28 |
|--------|-------|-------|--------|
|        | Mean  | SD    | Mean  | SD    | Mean  | SD    |
| I      | 66.67 | 3.72  | 67.83 | 6.08  | 66.67 | 6.89  |
| II     | 64.67 | 3.98  | 68.67 | 4.89  | 136.17| 4.96  |
| III    | 66.67 | 4.32  | 69.17 | 2.40  | 70.17 | 5.38  |
| IV     | 63.67 | 4.63  | 64.33 | 1.37  | 70.33 | 3.20  |
| V      | 63.17 | 3.49  | 67.33 | 4.37  | 105.67| 9.16  |
| VI     | 62.17 | 5.00  | 66.50 | 3.15  | 96.83 | 7.11  |
| VII    | 66.00 | 5.22  | 67.00 | 3.03  | 69.17 | 2.48  |
| VIII   | 66.33 | 3.93  | 73.50 | 10.31 | 71.00 | 9.03  |
| IX     | 66.83 | 4.40  | 67.50 | 6.25  | 61.83 | 2.32  |

SD- standard deviation; F- F statistic value of ANOVA; *- p-value <0.05=statistically significant
Table 3: Intergroup comparisons of duration of sucrose preference ratio in SPT using ANOVA at day 1 and day 28.

| Group | Before | After |
|-------|--------|-------|
| I     | Mean   | 0.905 | 0.907 |
|       | SD     | 0.027 | 0.022 |
| II    | Mean   | 0.902 | 0.523 |
|       | SD     | 0.052 | 0.077 |
| III   | Mean   | 0.913 | 0.883 |
|       | SD     | 0.048 | 0.026 |
| IV    | Mean   | 0.912 | 0.882 |
|       | SD     | 0.023 | 0.023 |
| V     | Mean   | 0.905 | 0.655 |
|       | SD     | 0.030 | 0.143 |
| VI    | Mean   | 0.913 | 0.687 |
|       | SD     | 0.033 | 0.043 |
| VII   | Mean   | 0.900 | 0.872 |
|       | SD     | 0.026 | 0.022 |
| VIII  | Mean   | 0.920 | 0.900 |
|       | SD     | 0.033 | 0.015 |
| IX    | Mean   | 0.912 | 0.908 |
|       | SD     | 0.036 | 0.022 |

Statistical significance (ANOVA) F=0.203; p=0.989
F=35.07; p=0.001

SD- standard deviation; F- F statistic value of ANOVA; *= p value<0.05= statistically significant

Tukey post hoc analysis showed there was a significant difference between the groups at day 28 (p<0.001). The mean duration of immobility and SPR in standard group IX (imipramine-15 mg/kg) when compared by Tukey post hoc analysis to experimental control Group II at day 28 a significant difference was found between the two groups (p<0.001). But there was no significant difference between the normal control Group I and Group IX (p=0.905).

The mean duration of immobility and SPR in all the test groups when compared by Tukey post hoc analysis to stress control group II at day 28 a significant difference was found (p<0.001). When compared to normal control group I no significant difference was found with group III, group IV, group VII and group VIII (p>0.05). These groups when compared to standard group IX also they did not shown any significant difference (p>0.05). But the test group V and test group VI showed significant difference with both group I and group IX (p<0.001).

**DISCUSSION**

Keeping the inflammatory pathology of depression in mind this study was designed to look for the preventive role of Aspirin and metformin in chronic stress induced depression and comparison with the standard anti-depressant drug Imipramine.

As per our results at day 1 there was no significant difference in duration of immobility in FST and sucrose preference ratio in SPT, which shows that the findings of all the groups were comparable before the start of the study and on day 2 also no statistically significant difference was observed. Day 2 evaluation was done to look for any acute effects of the drugs but in this study, no acute effect of any drug was observed in any of the treatment groups. This result can be justified as most of the anti-depressant actions of the drug is by the modulation in brain neurotransmission which takes the time of around 3 to 4 weeks. There is a time delay in the onset of response because the effect is due to long term neuronal adaptations rather than acute modulation of transporters and receptors.

At day 28 mean duration of immobility in FST and sucrose preference ratio in SPT was highest in the stress control group II in which only CUMS was given without any drug treatment. This shows that induction of CUMS can increase the immobility duration in the forced swim test. This result was also supported by the previous work which showed an increase in immobility duration after induction of CUMS in forced swim test. The similar type of result has been found in earlier study to look for the effect of stressor on sucrose preference test. It has been seen that rodents naturally have a preference for sweetened foods and drinks and when given a two-bottle free-choice regimen with access to both sucrose solution and regular water they show preference towards sucrose solution and this preference is lost when exposed to stress based models of depression like CUMS.

The mean duration of immobility and SPR in standard Group IX (imipramine 15 mg/kg) when compared to stress control group II at day 28 a significant difference was found between the two groups. This result showed that imipramine does not allow the immobility to increase in the forced swim test and SPR to decrease in sucrose preference test. A similar type of study was also performed previously on imipramine and they also demonstrated the decrease in immobility duration in FST after treatment with imipramine.

At day 28 the mean duration of immobility and SPR in the test group III (aspirin 30 mg/kg) and the test group IV (aspirin 60 mg/kg) at day 28 was not significantly increased from day 1. The above data showed that aspirin has positive effects on the prevention of depression as it decreases the immobility duration in FST in comparison to control group. The findings of our study are also supported by the study performed by Bhatt et al to look for the effect of aspirin in depression using experimentally induced model of depression with dexamethasone. They also found the decrease in immobility duration in forced swim test in rats receiving aspirin.

Our results demonstrated that effect of metformin was produced at both the doses as it was statistically significant from group II but not as much as standard group IX as significant difference was found between the two groups. This result can be supported by the study conducted by Shivavedi et al who used metformin in the dose of 25 mg/kg showed a decrease in immobility time in the forced swim test. Another study was also conducted which used metformin in the doses of 50, 75, 100, 150 mg/kg and found that metformin could prevent the methamphetamine induced behavioural changes more at high doses.
The significant results in combination group VII and group VIII was might be due to aspirin as metformin alone was not able to show the significant result as that of Imipramine. There was no significant difference between the combination groups and aspirin alone groups (p>0.05), this shows that there was no benefit of adding metformin with aspirin on immobility time in FST and sucrose preference in SPR test as per our findings. The possible mechanism for the above results is the anti-inflammatory role of aspirin and metformin in depression as described above. There are various studies to support these results for aspirin but there are very limited studies on the role of metformin in depression. However, details of the complete mechanism have not yet been explored.

CONCLUSION

The study demonstrated the possible role of aspirin and metformin in the prevention of depression. Aspirin at both the doses 30 mg/kg and 60 mg/kg showed positive and significant response nearly similar to that of imipramine a conventional tricyclic anti-depressant, while metformin at both the doses 50 mg/kg and 100 mg/kg showed improvement in comparison to control but it is not as efficacious as imipramine as appeared in our results. The response of the combination of aspirin and metformin was similar to aspirin alone or imipramine group. In the light of above evidence further experiments are required with more parameters like inflammatory markers and neurotransmitter levels to look for the preventive role of aspirin and metformin in depression.

Funding: Study was funded by intra mural seed grant, King George medical university, Lucknow, India

Conflict of interest: None declared

Ethical approval: Study was approved by institutional animal ethics committee, KGMU, Lucknow (Project no-97/IAEC/2018)

REFERENCES

1. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-75.
2. Holsboer F, Doerr HG, Gerken A, Müller OA, Sippell WG. Cortisol, 11-deoxycortisol and ACTH concentrations after dexamethasone in depressed patients and healthy volunteers. Psychiatr Res. 1984;11(1):15-23.
3. Maes M. The serotonin hypothesis of depression. Psychopharmacology: the fourth generation of progress. 1995:933-44.
4. Kohler O, Krogh J, Mors O, Benros EM. Inflammation in depression and the potential for anti-inflammatory treatment. Curr Neuropharmacol. 2016;14(7):732-42.
5. Hughes MM, Connor TJ, Harkin A. Stress-related immune markers in depression: implications for treatment. Int J Neuropsychopharmacol. 2016;19(6):1-19.
6. Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investigat Drugs. 2009;10(7):664.
7. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, et al. Regulation of the human serotonin transporter by interleukin-1β. Biochem Biophys Res Commun. 1995;216(2):560-7.
8. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, et al. Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis. Translat Psychiatr. 2017;7(5):1138.
9. Kaster MP, Gadotti VM, Calixto JB, Santos AR, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-α in mice. Neuropharmcol. 2012;62(1):419-26.
10. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46.
11. Grosser T, Smythe E, FitzGerald GA. Goodman & Gilman’s The pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill publishers; 2011.
12. Cadavid AP. Aspirin: the mechanism of action revisited in the context of pregnancy complications. Front Immunol. 2017;8:261.
13. Choi SH, Bosetti F. Cyclooxygenase-1 null mice show reduced neuroinflammation in response to β-amyloid. Aging. 2009;1(2):234.
14. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with Metformin use in subjects with type 2 diabetes. Diabetes Med. 2005;22(4):497-502.
15. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5.
16. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860.
17. Woo SL, Xu H, Li H, Zhao Y, Hu X, Zhao J, et al. Metformin ameliorates hepatic steatosis and inflammation without altering adipose phenotype in diet-induced obesity. PloS One. 2014;9(3):e91111.
18. Grippo AJ, Moffitt JA, Johnson AK. Cardiovascular alterations and autonomic imbalance in an experimental model of depression. Am J Physiol Regul Integr Comp Physiol. 2002;282(5):1333-41.
19. Tang M, Jiang P, Li H, Cai H, Liu Y, Gong H, et al. Antidepressant-like effect of n-3 PUFAs in CUMS rats: role of tPA/PAI-1 system. Physiol Behav. 2015;139:210-5.
20. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacol. 1987;93(3):358-64.
21. Fekadu N, Shibeshi W, Engidawork E. Major depressive disorder: pathophysiology and clinical management. J Depress Anxiety. 2017;6:255-7.
22. Bhatt S, Shukla P, Raval J, Goswami S. Role of Aspirin and dexamethasone against experimentally induced depression in rats. Basic Clin Pharmacol Toxicol. 2016;119(1):10-8.
23. Liu MY, Yin CY, Zhu LJ, Zhu XH, Xu C, Luo CX, et al. Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc. 2018;13(7):1686.
24. Goshen I, Kreisel T, Ben-Menachem-Zidon O, Licht T, Weidenfeld J, Ben-Hur T, et al. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatr. 2007;13(7):717-28.
25. Kitamura Y, Fujitani Y, Kitagawa K, Miyazaki T, Sagara H, Kawasaki H, et al. Effects of imipramine and bupropion on the duration of immobility of ACTH-treated rats in the forced swim test: involvement of the expression of 5-HT2A receptor mRNA. Biol Pharm Bull. 2008;31(2):246-9.
26. Shivavedi N, Kumar M, Tej GN, Nayak PK. Metformin and ascorbic acid combination therapy ameliorates type 2 diabetes mellitus and comorbid depression in rats. Brain Res. 2017;1674:1-9.
27. Keshavarzi S, Kermanshahi S, Karami L, Motaghinejad M, Motevalian M, Sadr S. Protective role of Metformin against methamphetamine induced anxiety, depression, cognition impairment and neurodegeneration in rat: the role of CREB/BDNF and Akt/GSK3 signaling pathways. Neurotoxicol. 2019;72:74-84.

Cite this article as: Abbas A, Kumar N, Singh S, Kumar R, Ahmad A, Nath R, et al. An experimental study to evaluate the role of aspirin and metformin in prevention of depression in rats. Int J Basic Clin Pharmacol 2020;9:605-10.